Affiliate Disclosure: This content contains affiliate links to health providers and services. BestMedsHub may receive compensation when you click through and take action. This compensation may impact how and where products and providers appear on this site. BestMedsHub does not include all providers or products available in the marketplace. This information is not medical advice — always consult a qualified healthcare professional.
Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.
Wegovy (Semaglutide) 2026: Cost, Dosing, Side Effects, and Who It’s Best For
Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~8 min read
Key Takeaways
- Active ingredient: Semaglutide 2.4 mg, once-weekly subcutaneous injection
- FDA approval: June 4, 2021 for chronic weight management; March 2024 expansion for cardiovascular risk reduction
- Average weight loss: ~15% body weight at 68 weeks (STEP-1 trial)
- Cash price 2026: $349/mo through NovoCare (intro $149/mo on 1.5 mg and 4 mg doses through June 30, 2026)
- With insurance + savings card: as low as $25/mo (commercial plans only)
- List price: $1,349.02/mo — pay this only if you have no insurance and skip NovoCare
Wegovy is Novo Nordisk’s branded semaglutide 2.4 mg, the first GLP-1 receptor agonist FDA-approved specifically for chronic weight management. In 2026, the fastest path to Wegovy is the NovoCare direct-to-patient program at $349/mo cash ($149/mo introductory on 1.5 mg and 4 mg through June 30, 2026), or a $25/mo copay with commercial insurance plus the manufacturer savings card. The list price remains $1,349.02/mo. Expect roughly 15% body weight loss over 68 weeks with full titration to the 2.4 mg maintenance dose.
How Wegovy Works (Mechanism of Action)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the endogenous GLP-1 hormone released by the gut after meals. Three things happen at once:
- Slowed gastric emptying — food stays in the stomach longer, prolonging satiety after meals.
- Central appetite suppression — semaglutide crosses into the hypothalamus and brainstem areas that control hunger, reducing food-seeking behavior and “food noise.”
- Glucose-dependent insulin secretion — the pancreas releases more insulin after carbohydrate meals, lowering post-meal blood glucose without causing hypoglycemia in non-diabetic patients.
Semaglutide’s 165-hour half-life is what makes once-weekly dosing possible. The molecule is engineered with a fatty acid side chain that lets it bind reversibly to albumin in the bloodstream, slowing renal clearance.
Wegovy Dosing Schedule
Wegovy uses a mandatory 16-week titration. Skipping or rushing escalation is the single biggest cause of GI side effects severe enough to force discontinuation.
| Week | Dose | Pen color |
|---|---|---|
| 1-4 | 0.25 mg weekly | Light grey |
| 5-8 | 0.5 mg weekly | Blue |
| 9-12 | 1.0 mg weekly | Yellow |
| 13-16 | 1.7 mg weekly | Purple |
| 17+ | 2.4 mg weekly (maintenance) | Dark blue |
| Advanced | 7.2 mg HD weekly | HD pen |
Prescribing schedule per Novo Nordisk Wegovy USPI. Verified May 2026 — subject to change with label updates.
Inject into the abdomen, thigh, or upper arm at the same day each week. If a dose is missed and the next dose is >48 hours away, take it; otherwise skip and resume on the next scheduled day. Two consecutive missed doses require re-titration from one step down.
Side Effects
The STEP-1 clinical trial reported these adverse events at 2.4 mg maintenance:
- Nausea — 44.2% (placebo 16.1%)
- Diarrhea — 29.7%
- Vomiting — 24.5%
- Constipation — 24.2%
- Abdominal pain — 20.4%
- Headache — 13.8%
- Fatigue — 11.0%
- Dyspepsia — 9.2%
- Dizziness — 7.7%
- Injection-site reactions — rare but reported
GI events were most pronounced during titration weeks and typically resolved within 2-4 weeks. About 4.5% of STEP-1 participants discontinued for GI reasons.
Serious warnings: Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent data; human relevance is unknown but the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other monitored risks: acute pancreatitis, acute gallbladder disease, acute kidney injury (usually dehydration-related), diabetic retinopathy complications in T2D, suicidal ideation, and pulmonary aspiration during general anesthesia (hold dose per ASA guidance). For a deeper breakdown of how these signals look in real-world data, see our 2026 GLP-1 side effects guide.
Cost in 2026
Five pricing paths exist for Wegovy in May 2026:
| Path | Monthly cost | Notes |
|---|---|---|
| NovoCare cash (1.5 mg / 4 mg intro) | $149/mo | Through June 30, 2026; 2 fills |
| NovoCare cash (0.25-2.4 mg starter intro) | $199/mo | 2 fills |
| NovoCare cash (maintenance) | $349/mo | All standard doses post-intro |
| NovoCare HD 7.2 mg | $399/mo | Advanced dose only |
| Commercial insurance + savings card | $25/mo copay | No Medicare/Medicaid |
| List price (no insurance, no NovoCare) | $1,349.02/mo | Avoid this path |
Pricing verified at NovoCare May 2026. Subject to change — check NovoCare directly for current pricing.
From July 1, 2026, the new Medicare “GLP-1 Bridge” program will cover all Wegovy pen forms for eligible beneficiaries. See our breakdown at GLP-1 with insurance and the head-to-head Wegovy vs Zepbound cost 2026 guide.
Who Wegovy Is Best For
Wegovy is FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease). It is also indicated for cardiovascular event risk reduction in overweight or obese adults with established CVD (SELECT trial, NEJM 2023).
You are a strong candidate if you: tolerate weekly injections, have commercial insurance with prior-auth pathways, want the GLP-1 with the longest safety record and clearest CV outcomes data, or qualify for NovoCare cash. Avoid if you have a personal or family history of MTC/MEN 2, prior pancreatitis, or active gallbladder disease. Compare options at our weight loss provider comparison hub or read the full Wegovy vs Zepbound comparison. For provider recommendations, see best GLP-1 telehealth in 2026.
Frequently Asked Questions
How much does Wegovy cost in 2026?
Wegovy is $349/mo cash through NovoCare on standard doses, with $149/mo introductory pricing on 1.5 mg and 4 mg through June 30, 2026, and $199/mo on starter doses. With commercial insurance and the savings card, copays drop to $25/mo. The list price without insurance or NovoCare is $1,349.02/mo. Medicare currently excludes Wegovy for obesity, but the new GLP-1 Bridge program covers Wegovy from July 1, 2026.
How much weight will I lose on Wegovy?
In the STEP-1 trial, adults on Wegovy 2.4 mg lost an average of 14.9% body weight over 68 weeks versus 2.4% on placebo. About one-third of participants lost ≥20% body weight. Results require full titration to maintenance and ongoing lifestyle changes; weight regain is common after discontinuation, with two-thirds of lost weight returning within 12 months in STEP-4.
What are the most common Wegovy side effects?
The most common side effects from STEP-1 are nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache (14%), and fatigue (11%). GI effects peak during dose escalation and usually fade within 2-4 weeks at each step. About 4.5% of trial participants discontinued for GI reasons. Serious risks include thyroid C-cell tumors (boxed warning), pancreatitis, and gallbladder disease.
Is Wegovy the same as Ozempic?
Both are semaglutide made by Novo Nordisk, but Wegovy is FDA-approved for chronic weight management (max dose 2.4 mg weekly, plus 7.2 mg HD) while Ozempic is approved for type 2 diabetes (max dose 2.0 mg weekly). The molecules are identical; the doses, indications, and pen colors differ. Ozempic is not approved for weight loss, although clinicians sometimes prescribe it off-label.
Who should not take Wegovy?
Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or prior serious hypersensitivity to semaglutide. Avoid during pregnancy (discontinue 2 months before planned conception). Use caution in patients with a history of pancreatitis, gallbladder disease, severe gastroparesis, or active diabetic retinopathy.
How long do you stay on Wegovy?
Wegovy is intended for chronic, long-term use. Obesity is a chronic disease, and STEP-4 showed that stopping the drug led to two-thirds of lost weight returning within 12 months. Most clinicians treat Wegovy as an indefinite maintenance medication, similar to antihypertensives or statins, with periodic reassessment of dose, side effects, and continued benefit.
Does insurance cover Wegovy?
Most major commercial group plans cover Wegovy with prior authorization requiring BMI ≥30, or BMI ≥27 with comorbidity. Some plans (notably CVS Caremark) require step therapy through Contrave first. Traditional Medicare currently excludes Wegovy for obesity, but the new GLP-1 Bridge program begins July 1, 2026, covering all Wegovy pen forms. Medicaid coverage varies by state. With commercial insurance plus the manufacturer savings card, copays can be as low as $25/mo.
Can I get Wegovy through telehealth?
Yes. Ro and WeightWatchers Clinic (formerly Sequence) are official Wegovy telehealth partners and can prescribe brand-name semaglutide nationally. Teladoc Health and many primary-care telehealth services also prescribe Wegovy with insurance routing. Novo Nordisk ended its Hims partnership in June 2025, so Hims no longer offers brand Wegovy. Compounded semaglutide is a separate (non-FDA-approved) product offered by 503A pharmacies via providers like Mochi and Henry Meds.
Wegovy vs Zepbound — which works better?
In the SURMOUNT-5 head-to-head trial (Eli Lilly, December 2024), Zepbound 15 mg produced about 20.2% body weight loss versus 13.7% for Wegovy 2.4 mg at 72 weeks. Zepbound also had lower nausea rates. Wegovy has stronger cardiovascular outcomes evidence (SELECT trial). Choice depends on insurance coverage, side-effect tolerance, and access. See our full Wegovy vs Zepbound comparison.
Can I drink alcohol on Wegovy?
There is no formal contraindication, but most clinicians advise minimizing alcohol on Wegovy. Alcohol can worsen GI side effects (nausea, vomiting), increase risk of pancreatitis (alcohol is a known precipitant), and may amplify hypoglycemia risk if you also take insulin or sulfonylureas. Anecdotally, many Wegovy patients report a sharply reduced desire to drink due to the drug’s central appetite-suppressing effects.
Sources
- NovoCare Wegovy pricing and savings (Novo Nordisk) — verified May 2026
- Novo Nordisk Wegovy product page
- FDA news release: Wegovy approval, June 4, 2021
- Wilding et al., STEP-1 trial, NEJM 2021
- Lincoff et al., SELECT cardiovascular outcomes, NEJM 2023
- Wegovy US Prescribing Information (FDA label)
Medical disclaimer: Information here is educational only. GLP-1 medications can cause serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Consult a licensed clinician before starting, switching, or stopping any prescription weight-loss medication.